The emerging role of CDK4/6i in HER2-positive breast cancer

Prior to the advent of the monoclonal antibody trastuzumab, human epidermal growth-factor receptor 2 (HER2)-positive (HER2+) breast cancer (BC) was associated with an aggressive clinical course and poor survival outcomes. In the era of effective HER2-directed therapies, median survival rates for pat...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Sullivan, Ciara C., Suman, Vera J., Goetz, Matthew P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887797/
https://www.ncbi.nlm.nih.gov/pubmed/31832106
http://dx.doi.org/10.1177/1758835919887665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887797/
https://www.ncbi.nlm.nih.gov/pubmed/31832106
http://dx.doi.org/10.1177/1758835919887665

Ejemplares similares